349 related articles for article (PubMed ID: 23335221)
21. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
22. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Hensley ML
Curr Opin Oncol; 2010 Jul; 22(4):356-61. PubMed ID: 20520541
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
24. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
26. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
Miller BE; Blessing JA; Stehman FB; Shahin MS; Yamada SD; Secord AA; Warshal DP; Abulafia O; Richards WE; Van Le L
Gynecol Oncol; 2010 Aug; 118(2):139-44. PubMed ID: 20452658
[TBL] [Abstract][Full Text] [Related]
27. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine/docetaxel--welcome to a new standard.
Fleming G
Gynecol Oncol; 2008 Jun; 109(3):313-5. PubMed ID: 18534248
[No Abstract] [Full Text] [Related]
31. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy regimen for recurrent uterine leiomyosarcoma.
Hu F; Ye Y; Begum H
J Oncol Pharm Pract; 2024 Mar; 30(2):400-403. PubMed ID: 37787402
[TBL] [Abstract][Full Text] [Related]
35. Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Mahdi H; Rizzo A; Rose PG
Int J Gynecol Cancer; 2015 Mar; 25(3):467-73. PubMed ID: 25695549
[TBL] [Abstract][Full Text] [Related]
36. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Ebeling P; Eisele L; Schuett P; Bauer S; Schuette J; Moritz T; Seeber S; Flasshove M
Onkologie; 2008 Feb; 31(1-2):11-6. PubMed ID: 18268394
[TBL] [Abstract][Full Text] [Related]
38. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
40. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
Gadducci A; Grosso F; Scambia G; Raspagliesi F; Colombo N; Grignani G; Casali P; Sanfilippo R; Buonadonna A; Santoro A; Bruzzone M; Artioli G; Lorusso D; Biagioli E; Fossati R; Galli F; Negri E; Rulli E; Torri V; D'Incalci M
Br J Cancer; 2018 Aug; 119(5):565-571. PubMed ID: 30057406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
